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ABSTRACT
We report the identification of a novel pharmacological profile
for the leukotriene (LT)C4 binding site we previously identified in
human lung parenchyma (HLP). We used a series of classic
cysteinyl-LT (CysLT)1 receptor antagonists belonging to differ-
ent chemical classes and the dual CysLT1-CysLT2 antagonist
BAY u9773 for both binding and functional studies. Because
the presence of (S)-decyl-glutathione interfered with cystei-
nyl-LT binding, with a kinetic protocol we avoided the use of
this compound. By means of heterologous dissociation time
courses, we demonstrated that zafirlukast, iralukast, and BAY
u9773 selectively competed only for 3H-LTD4 binding sites,
whereas pobilukast, pranlukast, and CGP 57698 dissociated
both 3H-LTC4 and
3H-LTD4 from their binding sites. Thus, with
binding studies, we have been able to identify a pharmacolog-
ical profile for LTC4 distinct from that of LTD4 receptor (CysLT1)
in HLP. On the contrary, in functional studies, all of the classic
antagonists tested were able to revert both LTC4- and LTD4-
induced contractions of isolated HLP strips. Thus, LTD4 and
LTC4 contract isolated HLP strips through the same CysLT1
receptor. The results of kinetic binding studies, coupled to a
sophisticated data analysis, confirm our hypothesis that HLP
membranes contain two cysteinyl-LT high-affinity binding sites
with different pharmacological profiles. In functional studies,
however, LTD4- and LTC4-induced contractions are mediated
by the same CysLT1 receptor. In conclusion, the specific LTC4
high-affinity binding site cannot be classified as one of the
officially recognized CysLT receptors, and it is not implicated in
LTC4-induced HLP strip contractions.
It has long been accepted that cysteine-containing leuko-
trienes (cysteinyl-LTs) LTC4, LTD4, and LTE4, play an im-
portant role in asthma, participating in both the bronchocon-
striction and the chronic inflammatory component of the
disease. CysLTs originate from the oxidative metabolism of
arachidonic acid through a key enzyme, 5-lipoxygenase, in a
number of inflammatory cells, including eosinophils, ba-
sophils, mast cells, and macrophages (Drazen and Austen,
1987; Hay et al., 1995).
CysLTs exert their actions through the activation of
specific receptors, the first of which was recently cloned
(Lynch et al., 1999). However, in human airways, all the
interest has been focused on LTD4, whereas LTC4 has been
considered either only a precursor or an equipotent/equief-
fective agonist (Buckner et al., 1986) and LTE4 has been
considered as a metabolite with partial agonist activity
(Saussy et al., 1989). Moreover, it is generally believed
that in human airways, LTC4 acts on the same receptor as
LTD4, either CysLT1 in bronchi (Buckner et al., 1986,
1990; Hay et al., 1987) or CysLT2 in human pulmonary
veins (Labat et al., 1992).
We recently pointed out that in human lung parenchyma
(HLP) membranes, LTC4 possesses a specific high-affinity
binding site with characteristics distinct from those of LTD4
(Capra et al., 1998). In particular, in this tissue, two of the
classic CysLT1 antagonists [i.e., pobilukast and ICI 198,615
(from which zafirlukast has been derived)] behaved differ-
ently against 3H-LTC4 and
3H-LTD4 at equilibrium, thus
suggesting the idea that two different receptors might exist.
However, all of the experiments have been performed in the
presence of (S)-decyl-glutathione [(S)-decyl-GSH], a com-
pound devoid of either agonist or antagonist activities, which,
as it will be demonstrated, interferes with antagonist binding
and prevents a complete pharmacological characterization.
On the basis of these results, we avoided the use of (S)-decyl-
GSH and characterized these two distinct binding sites with
a series of antagonists (Fig. 1) in both kinetic binding studies
in HLP membranes and contraction of HLP strips.
ABBREVIATIONS: Cysteinyl-LT, cysteine-containing leukotrienes; LT, leukotriene; (S)-decyl-GSH, (S)-decyl-glutathione; PG, prostaglandin; HLP,
human lung parenchyma; Gpp(NH)p, guanosine-59-(b,g-imido)triphosphate.
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Experimental Procedures
Materials. 3H-LTC4 (164–173 Ci/mmol) and
3H-LTD4 (164–173
Ci/mmol) were purchased from DuPont NEN (Boston, MA). LTC4
and prostaglandin (PG)F2a were purchased from Cayman Chemical
Co. (Ann Arbor, MI). Pobilukast (SKF 104353) was kindly provided
by SmithKline and Beecham Laboratories (King of Prussia, PA).
LTD4, zafirlukast (ICI 204,219), pranlukast (ONO 1078), iralukast
(CGP 45715A), and CGP 57698 were a generous gift of Dr. A. von
Sprecher (Novartis, Basel, Switzerland). Guanosine-59-(b,g-imido)
triphosphate [Gpp(NH)p], (S)-decyl-GSH, cysteine, glycine, boric
acid, serine, indomethacin, Tyrode’s salts, and HEPES were pur-
chased from Sigma Chemical Co. (St Louis, MO). Filtercount was
from Packard Instruments Co. (Meriden, CT). All the reagents used
in HPLC analysis were of analytical grade and purchased from Carlo
Erba (Milan, Italy), as were GF/C Whatman Fiberglas filters.
Preparation of HLP Membranes. Crude membranes were pre-
pared from macroscopically normal specimens removed at thoracot-
omy for lung cancer as previously described (Rovati et al., 1985).
Briefly, specimens were minced, homogenized at 4° in 10 mM
HEPES buffer, pH 7.4 (1:24, w/v), and centrifuged at 770g for 10 min,
and the supernatant was centrifuged at 27,000g for 20 min. The
pellet was resuspended, centrifuged under the same condition, and
finally resuspended in 5% of the homogenization volume. Membrane
aliquots were frozen at 280° and stored for no longer than 3 months.
Protein content was determined according to the Bradford dye-bind-
ing protein assay (Pierce Chemical Co., Rockford, IL). Before use,
serine-borate complex (40 mM final concentration in the assay, pre-
pared as an equimolar solution of serine and boric acid), cysteine (10
mM), and glycine (10 mM) were added to the membrane suspension
to avoid cysteinyl-LT metabolism.
Reverse Phase HPLC. Labeled and unlabeled leukotriene purity
was always assessed by reverse phase HPLC. Only leukotrienes with
a purity grade greater than or equal to 90% were used. The Beckman
HPLC system was equipped with a 110B Solvent Delivery Module,
an ODS Ultrasphere C18 column, and a programmable detector
module 166 set at 280 nm. Both labeled and unlabeled leukotrienes
were eluted isocratically with a filtered and degassed mixture of
CH3OH:H2O:CH3COOH (65:35:0.02 v/v/v), adjusted at pH 5.8 with
NH4OH, at a flow rate of 1 ml/min. To check the purity of tritiated
leukotrienes, fractions were collected every 30 s, and the radioactiv-
ity profile assessed by liquid scintillation counting (Ultima Gold;
Packard).
Binding Studies. Equilibrium binding studies were performed at
25°C for 30 min with 0.5 nM 3H-LTD4 or
3H-LTC4 and unlabeled
homologous or heterologous ligands at the indicated concentrations,
in the absence and presence of 10 mM (S)-decyl-GSH.
Association time courses were performed at 25°C with 0.5 nM
3H-LTC4 or
3H-LTD4 to label the high-affinity binding sites and with
a total ligand concentration of 0.1 mM (mixture of 1 nM labeled
ligand plus 0.1 mM unlabeled homologous ligand) to also label the
low-affinity sites. The experiments were conducted for 30 or 60 min
for 3H-LTD4 and
3H-LTC4, respectively. Dissociation was induced by
Fig. 1. Chemical structures of LTC4, LTD4, and receptor antagonists.
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the addition of 1 mM unlabeled leukotriene (homologous dissociation)
or 10 mM unlabeled antagonist (heterologous dissociation). Gp-
p(NH)p was used at a concentration of 30 mM where indicated.
In both equilibrium and kinetic studies, HLP membranes (0.25
mg/sample), 10 mM HEPES-KOH, pH 7.4, and 1 mM CaCl2 were
added to the incubation mixture to achieve a final volume of 250 ml.
Unbound ligand was separated by rapid vacuum filtration (Brandel
Cell Harvester) onto glass-fiber GF/C filters (Whatman) soaked in
2.5% polyvinyl alcohol, and the filters were washed twice with 4 ml
of HEPES buffer at 4°C. Radioactivity was measured in a liquid
scintillation counter (Filter Count; Packard).
Isolated HLP Strip Preparation. Strips of HLP (1.5–2 cm) were
prepared from macroscopically normal human lung specimens
placed in cold (4°C) saline solution and studied within 120 min from
resection. The HLP strips were suspended in 5-ml organ baths con-
taining Tyrode’s solution (composed of 140 mM NaCl, 3 mM KCl, 1
mM CaCl2, 0.05 mM MgCl2, 0.5 mM NaH2PO4, 8.4 mM glucose, and
12 mM NaHCO3), maintained at 37°C, and bubbled with 95% O2, 5%
CO2, pH 7.4. Contractions were measured with a Basile 7004 iso-
metric force transducer and recorded on a Basile Gemini 7070 poly-
graph. HLP strips were set at an initial tension of 1 g, washed with
fresh buffer every 15 min over a 60-min equilibration period, and
then treated with 40 mM serine-borate complex and 3 mM L-cysteine
to inhibit LTC4 and LTD4 metabolism. For antagonist studies, after
15 min, cumulative concentration-response curves were obtained
with an increasing concentration of LTC4 or LTD4 (0.1 nM to 1 mM).
At 15 min later, either a concentration of 10 mM of each antagonist
tested or the vehicle DMSO was added. Only one LTC4 or LTD4
concentration-response curve was obtained from each HLP strip. The
contractile response to each concentration of LTC4 or LTD4 was
expressed as percent of the maximal response to 300 mM PGF2a.
Computer Analysis. Analysis of binding data of association and
homologous dissociation time-courses was performed using the pro-
gram KINFIT II (Rovati et al., 1996) The computerized analysis of
the data through KINFIT II has several advantages, as it allows 1)
simultaneously analysis of association and dissociation time courses;
Fig. 2. Effect of (S)-decyl-GSH on the ability of agonist and antagonist to
dissociate 3H-LTC4 and
3H-LTD4 binding at equilibrium. A, effect of 10
mM (S)-decyl-GSH on displacement of 1 mM LTC4 and 10 mM concentra-
tion of the indicated antagonists versus 3H-LTC4. B, effect of 10 mM
(S)-decyl-GSH on displacement of 1 mM LTD4 and 10 mM concentration of
the indicated antagonists versus 3H-LTD4. Data are expressed as mean 6
S.E. of three replicates from at least three experiments.
Fig. 3. Effect of (S)-decyl-GSH on 3H-LTC4 and antagonist binding in
kinetic studies. A, dissociation time courses of 3H-LTC4 in the absence (F)
and presence (E) of 10 mM (S)-decyl-GSH. Inset, parameters C (amount
bound, nM) and koff (s
21) of the curves shown. B, heterologous dissocia-
tion time courses for 10 mM pranlukast versus 3H-LTC4 in the absence
(l) and presence (L) of 10 mM (S)-decyl-GSH. Inset, parameters C
(percent specific binding) and koff (s
21) of the curves shown. Data are
mean values of two replicates from a single experiment, representative of
at least two other experiments.
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2) calculation of kon, koff, and Bmax directly in the same analysis
without any further approximation; 3) performance of association
time courses using a mixture of labeled and unlabeled ligands; and 4)
selective labeling of a high-affinity/low-capacity class of sites using a
low-specific-activity compound. Binding is expressed as specific
bound concentration versus time.
Data from heterologous dissociation time courses were analyzed
using EXPFIT (Guardabasso et al., 1988), which calculates the coef-
ficients C (amount or percent bound) and R (the apparent rate
constant for the specified antagonist). No direct calculation of koff
was possible for the heterologous dissociation time courses. Biphasic
dissociation time courses represent interaction with a heterologous
population of sites, where the fast dissociation rate represents the
low-affinity component and the low dissociation rate represents the
high-affinity component. Antagonist competition is expressed as per-
cent dissociation specific binding.
Statistical analysis of concentration-response curves was per-
formed by using the computer program ALLFIT (De Lean et al.,
1978), which calculates the lower and upper plateaus, the slope, and
the EC50 value.
Different models of increasing complexity were selected using the
statistical principle of the “extra sum of squares” (Draper and Smith,
1966). Parameter errors are always expressed in percent coefficient
of variation (% CV). A statistical level of significance of P , .05 was
accepted. All of the curves shown were computer generated.
Results
Effect of (S)-Decyl-GSH on 3H-LTC4 and
3H-LTD4
Binding. The ability of a series of antagonists (10 mM) to
compete for 3H-LTC4 binding was assessed at equilibrium
(Fig. 2A). In the presence of (S)-decyl-GSH, only pobilukast
retained the ability to displace 3H-LTC4 from its binding
sites, whereas no appreciable effect was observed for agonist
binding. The same experiment was repeated using 3H-LTD4
in the absence and presence of 10 mM (S)-decyl-GSH. In the
absence of (S)-decyl-GSH, all of the antagonists tested were
able to inhibit 3H-LTD4 binding, whereas in the presence of
(S)-decyl-GSH, the profile of antagonism was identical to
that obtained versus 3H-LTC4 (Fig. 2B).
In Fig. 3 we tested the ability of (S)-decyl-GSH to interfere
with 3H-LTC4 binding in kinetic studies. Dissociation time
courses are biphasic (P , .05), representing interaction with
a heterologous population of sites, where the fast dissociation
rate represents the low-affinity component and the low dis-
sociation rate represents the high-affinity component. (S)-
Decyl-GSH did not affect the kinetic parameters but abol-
ished 75% of 3H-LTC4 specific binding [ratio of the specific
binding, C1 1 C2, in the absence and presence of (S)-decyl-
GSH; Fig. 3A]. Furthermore, (S)-decyl-GSH prevented pran-
lukast- induced dissociation of 3H-LTC4 from its high-affinity
binding site (Fig. 3B). On the basis of these results, all of the
subsequent experiments were performed using a kinetic pro-





LTC4 association time courses were performed at different
concentrations of total ligand (see Experimental Procedures):
0.5 nM to prevalently label the high-affinity sites (Figs. 4 and
5, respectively, and Table 1) and 0.1 mM to also label the
low-affinity sites (Table 1). Both dissociation curves are bi-
phasic. Simultaneous computerized analysis of association
and dissociation time courses performed at different total
ligand concentrations confirmed the presence of two classes
of binding sites for both LTC4 and LTD4 (P , .05). Parame-
ters are reported in Table 1.
Shown are 3H-LTD4 and
3H-LTC4 (Figs. 4 and 5, insets,
respectively) dissociation time courses performed in the ab-
sence and presence of 30 mM Gpp(NH)p, a nonhydrolyzable
GTP analog. Gpp(NH)p was able to almost completely shift
the high-affinity 3H-LTD4 binding to its low-affinity compo-
nent [from 38 to 89% low-affinity site in the absence and
Fig. 4. Association and dissociation
time courses for 3H-LTD4. F, 0.5 nM
3H-LTD4 in the association phase; dis-
sociation was induced by 1 mM LTD4.
E, 10 nM total LTD4 (2 nM
3H-LTD4
plus 8 nM LTD4) in the association
phase; dissociation was induced by 1
mM LTD4. Inset, 0.5 nM
3H-LTD4 in
the association phase (data not
shown); dissociation was induced by 1
mM LTD4 in the absence (F) and in the
presence () of 30 mM Gpp(NH)p. Data
are mean values of three replicates
from a single experiment, representa-
tive of at least two other experiments.
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presence of Gpp(NH)p, respectively]. On the contrary, Gp-
p(NH)p had no effect on the high-affinity site labeled by
3H-LTC4.
Antagonist Binding Studies. Heterologous dissociation
time courses were performed with a series of “classic” CysLT1
antagonists (Brooks and Summers, 1996) and the dual an-
tagonist BAY u9773 (Cuthbert et al., 1991).
All of the antagonists tested (Table 2) were able to disso-
ciate 3H-LTD4 from its binding sites. Figure 6A shows the
curves for three of these antagonists (the others are not
shown for the sake of clarity) in comparison with the homol-
ogous curve. All antagonist-induced 3H-LTD4 dissociation
curves were biphasic (P , .05). On the contrary, only pobi-
lukast, pranlukast, and CGP 57698 dissociated 3H-LTC4
from its high-affinity binding sites, whereas zafirlukast,
iralukast, and BAY u9773 did not (Fig. 6B and Table 2).
Again, only three curves are shown for the sake of clarity.
The apparent potencies of the different antagonists in dis-
placing 3H-LTC4 and
3H-LTD4 are presented in Table 2 as
percent dissociation at 60 min.
Isometric Contraction of Isolated HLP Strips. Figure
7 shows LTD4 and LTC4 cumulative concentration-response
curves obtained from isometric contractions of HLP strips.
The EC50 values are 6.6 nM 646% CV and 91 nM 63.3% CV,
and the maximal contractions (expressed as percent versus
PGF2a) are 190 6 9.5% CV and 111 6 3.5% CV for LTD4 and
LTC4, respectively.
All of the antagonists were tested up to a concentration of
10 mM and were able to completely reverse (.85%) both
LTD4- and LTC4-induced contractions, with the only excep-
tion of BAY u9773. The dual antagonist was less active than
the other compounds with a maximal inhibition lower than
50% (data not shown), and BAY u9773 presented a partial
agonist activity in most of the experiments. Tracings from a
typical experiment for pranlukast and iralukast versus LTC4
are shown in Fig. 8, A and B, respectively.
Discussion
It is well known that LTC4 predominantly binds to a num-
ber of nonreceptor sites in cellular membranes (Keppler,
Fig. 5. Association and dissociation time
courses for 3H-LTC4. f, 0.5 nM
3H-LTC4
in the association phase; dissociation was
induced by 1 mM LTC4. Inset, 0.5 nM
3H-
LTC4 in the association phase (data not
shown); dissociation was induced by 1 mM
LTC4 in the absence (f) and in the pres-
ence (M) of 30 mM Gpp(NH)p. Data are
mean values of three replicates from a
single experiment, representative of at
least two other experiments.
TABLE 1
Kinetic parameters for 3H-LTD4 and
3H-LTC4
kon values are expressed in M
21 z s21. koff values are expressed as s
21. Kd values are the ratio of koff to kon and are expressed in nM. Bmax values are expressed as pmol/mg
protein. Parameters are expressed as mean 6 % CV.
3H-LTD4
3H-LTC4
kon1 2.7 3 10
6 6 28 1.5 3 107 6 96
Kd1 0.063 Kd1 0.053
koff1 1.7 3 10
24 6 39 7.8 3 1024 6 33
Bmax1 0.0073 6 17 0.0095 6 42
kon2 1.8 3 10
5 6 85 3.3 3 105 6 51
Kd2 21.7 Kd2 83
koff2 4 3 10
23 6 45 2.7 3 1022 6 35
Bmax2 0.074 6 87 5.5 6 26
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1992; Metters et al., 1994). As we previously demonstrated
(Capra et al., 1998), to unmask a specific high-affinity bind-
ing site for LTC4, (S)-decyl-GSH must be routinely included
in the 3H-LTC4 binding assay at equilibrium to inhibit the
interaction with most of these lower-affinity nonreceptor
sites. However, we observed that all of the antagonists
tested, with the exception of pobilukast, were unable to com-
pete for 3H-LTC4 binding in the presence of (S)-decyl-GSH.
To elucidate whether (S)-decyl-GSH might interfere with the
antagonist binding, we selected one representative com-
pound from each structural class of antagonists and tested
them in HLP membranes, also against 3H-LTD4 in the ab-
sence and presence of (S)-decyl-GSH. Surprisingly, in the
presence of (S)-decyl-GSH, the antagonists were unable to
also compete for 3H-LTD4, indicating that this compound
interferes with antagonist but not with agonist binding (Fig.
2). Interestingly, only the binding of pobilukast, the antago-
TABLE 2
Antagonist-induced dissociation at 60 min
Parameters are expressed as mean 6 % CV.
3H-LTD4
3H-LTC4
% dissociation at 60 min
Pobilukast 47 6 42 53 6 12
Pranlukast 75 6 10 38 6 47
CGP 57698 69 6 31 46 6 21
Zafirlukast 62 6 3 N.D.
Iralukast 52 6 8 N.D.
BAY u9773 47 6 12 N.D.
N.D., not detectable.
Fig. 6. Homologous and heterologous dissociation time courses. A, la-
beled ligand 0.5 nM 3H-LTD4; dissociation was induced by 1 mM LTD4
(F), 10 mM pobilukast (), zafirlukast (L), and BAY u9773 (M). B, labeled
ligand 0.5 nM 3H-LTC4; dissociation was induced by 1 mM LTC4 (f), 10
mM pobilukast (), zafirlukast (L), and BAY u9773 (M). Data are mean
values of three replicates from a single experiment, representative of at
least two other experiments. S.E. values are not shown for the sake of
clarity.
Fig. 7. Cumulative concentration-response curves of LTD4- (F) and LTC4-
(f) induced contraction of isolated HLP strips. Data are mean values of
four to six replicates 6 S.E.
Fig. 8. Effect of pranlukast (A) and iralukast (B) on cumulative concen-
tration-response curve of LTC4 in isolated HLP strips. Data are from a
single experiment, representative of at least two other experiments.
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nist with the structure closest to that of cysteinyl-LTs, was
not affected by (S)-decyl-GSH.
Because the presence of (S)-decyl-GSH prevents the phar-
macological characterization of 3H-LTC4 binding at equilib-
rium, to avoid the use of (S)-decyl-GSH, we have performed
the pharmacological characterization of the 3H-LTC4 high-
affinity site by means of kinetic binding studies. This protocol
is rarely used for this purpose, yet in this specific case, with
Kd1 far apart from Kd2 (1600-fold difference), it is possible to
choose a concentration of 3H-LTC4 to saturate the high-
affinity/low-capacity site without saturating the low-affinity/
high-capacity site in the association phase (Rovati et al.,
1996; Rovati, 1998). Clearly, a portion of the low-affinity
sites, due to their abundance, is also labeled (dissociation
time courses are always biphasic). However, with this ap-
proach, there is no longer a need to inhibit the binding to the
lower-affinity sites by means of (S)-decyl-GSH. The same also
applies, in part, to 3H-LTD4, despite the difference between
Kd1 and Kd2 being only 340-fold.
Thus, having primarily labeled the high-affinity binding
sites, one can perturb the equilibrium with the antagonists to
asses their ability to dissociate 3H-LTD4 and
3H-LTC4 from
both sites. This protocol is indeed a heterologous dissociation
time course, which allow a study of the interaction of unla-
beled ligands (i.e., the antagonists) with 3H-LTD4 and
3H-
LTC4. The only limitation of this type of protocol is that no
dissociation constants for the antagonist can be calculated,
but only their apparent potency order (Table 2).
We observed that (S)-decyl-GSH interferes with antago-
nist-induced 3H-LTC4 dissociation from its high-affinity sites
without interfering with the kinetic parameters of the ago-
nist (Fig. 3), confirming the data obtained at equilibrium. A
possible explanation for these findings could reside in a non-
total coincidence of agonist and antagonist sites on CysLT
receptors and in the steric hindrance of (S)-decyl-GSH at the
antagonist binding site.
The results obtained from the simultaneous computerized
analysis of association and dissociation time courses for 3H-
LTD4 and
3H-LTC4 confirmed the model and parameters
(Table 1) for cysteinyl-LT binding sites in HLP (Capra et al.,
1998), thus validating the kinetic approach in the absence of
(S)-decyl-GSH. In fact, LTD4 interacts with two interconvert-
ible states of a G protein-coupled receptor, whereas LTC4
displays a different kinetic profile, and both sites are GTP
insensitive.
Heterologous dissociation time courses indicated that
among all of the “classic” CysLT1 antagonists we tested, only
pobilukast, pranlukast, and CGP 57698 were able to dissoci-
ate both 3H-LTD4 and
3H-LTC4 from their high- and low-
affinity binding sites. On the contrary, zafirlukast and
iralukast were unable to interact with the 3H-LTC4 high-
affinity binding site (Fig. 6 and Table 2), whereas they retain
the ability to dissociate the ligand from the nonreceptor sites
(low-affinity component). Hence, 3H-LTC4 high-affinity bind-
ing site has a unique pharmacological profile, suggesting the
existence of a specific LTC4 receptor different from that of
LTD4 (CysLT1).
Among all of the cysteinyl-LT antagonists available, BAY
u9773 is, until now, the only compound able to recognize both
CysLT1 and CysLT2 receptors (Coleman et al., 1995). In HLP
membranes, BAY u9773 is indeed able to dissociate 3H-LTD4
from both of its sites but is unable to dissociate 3H-LTC4 from
its high-affinity sites, thus excluding that this LTC4 specific
site is a CysLT2 receptor.
Taken together, these binding data confirm our hypothesis
that HLP membranes contain two cysteinyl-LT high-affinity
binding sites with different kinetic (sensitivity to GTP) and
pharmacological profiles. LTD4 binding sites can be classified
as a CysLT1 receptor (Lynch et al., 1999), whereas LTC4
high-affinity binding site is neither a CysLT1 nor a CysLT2
receptor. Moreover, these results indicate that classic antag-
onists should no longer be considered a homogeneous class of
compounds with respect to LTC4 binding sites and that their
specificity seems to be unrelated to the chemical structure,
because antagonists of the same class (e.g., pobilukast,
iralukast, and BAY u997) behave differently versus the two
different receptors.
It is well known that in human airways, CysLT1 receptors
predominantly mediate the contraction of smooth muscle
tissue, thus playing an important role in the acute phase of
asthma. To evaluate whether LTD4 and LTC4 share the same
effect and the same pharmacological profile in isolated HLP
strips, all of the antagonists were also tested in a functional
assay against LTD4- and LTC4-induced contractions. Despite
the fact that LTD4 and LTC4 have different potencies (14-fold
difference) and efficacies (1.7-fold difference; Fig. 7), all of the
classic antagonists tested were able to reverse LTD4- as well
as LTC4-induced contractions up to 85 to 100%. BAY u9773
showed a lower efficacy (60% inhibition of LTD4- and LTC4-
induced contractions at the same time point), suggesting it
could behave as a partial agonist, as already proposed both in
this tissue (Wikstrom Jonsson et al., 1998) and in human
pulmonary veins (Gardiner et al., 1994).
Thus, we can conclude that LTD4 and LTC4 contract iso-
lated HLP strips through the same CysLT1 receptor, as al-
ready suggested by Gardiner and Cuthbert (1988) on the
basis of more limited data (only one antagonist, FPL 55712).
The specific and characteristic LTC4 high-affinity binding
site cannot be classified among one of the officially recognized
CysLT receptors, nor it is implicated in LTC4-induced HLP
strip contractions. The recent cloning of the CysLT1 receptor
(Lynch et al., 1999) will rapidly lead to the identification and
characterization of the different classes and subclasses of
CysLT receptors, but the LTC4 specific binding site identified
here is unlikely to be one of these. In fact, this binding site is
not GTP sensitive (Fig. 5 and Capra et al., 1998) and thus
should not belong to the superfamily of seven-transmem-
brane domain receptors.
It is tempting to speculate that this putative receptor is
implicated in aspects of the asthmatic syndrome different
from bronchoconstriction, such as smooth muscle hyperpla-
sia and proliferation or mucus secretion. Indeed, there are
data in the literature that indicate a proliferative role of
cysteinyl-LTs in human airway epithelial (Leikauf et al.,
1990) or smooth muscle (Panettieri et al., 1998) cells. These
data not only suggest LTC4 as a more potent mitogenic stim-
ulus than LTD4 (Leikauf et al., 1990) but also indicate LTD4
to be a weak agonist with a different pharmacological profile
compared with the classic contractile function mediated by
the CysLT1 receptor.
Although direct evidence to correlate proliferation with the
putative LTC4 receptor is still lacking, our findings might
prompt a deeper investigation into the role of LTC4, not only
as a precursor of LTD4/LTE4 but also as an active indepen-
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dent agonist per se. This in turn might contribute to the
discovery and development of new and more active drugs
with a wider spectrum of action to be used in the treatment
of an overlooked disease such as asthma.
Finally, our data also suggest that the homologous kinetic
protocol is a valid alternative to classic equilibrium binding
studies when supported by sophisticated data analysis. The
intrinsic complexity of these experiments can be easily offset
by the advantages that this type of protocol presents in
particular biological systems where equilibrium studies
might fail for theoretical or practical reasons (e.g., when one
deals with a high-affinity ligand with a low specific activity;
Rovati, 1998). Moreover, heterologous dissociation time
courses, albeit with the limitation previously discussed, ap-
pear to be a powerful tool for the study of the kinetic char-
acteristics of compounds not available in the labeled form.
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